



Paper # 12152004

Form PTO-1449  US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/612,476
				Filing Date	
				First Named Inventor	Patrick T. PRENDERGAST
				Art Unit	1614
				Examiner Name	Ray Henley
				Confirmation No.	
Sheet 1 of 3	Attorney Docket No.	802_004 CON			

**U.S. PATENT DOCUMENTS**

Exam. Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
[Signature]	5,932,596	8/1999	Shih, et al.	[Signature]		
	5,849,782	12/1998	Beal			
	5,691,338	11/1997	Prochaska et al.			
	5,686,436	11/1997	Van Dyke			
	5,668,117	9/1997	Shapiro			
	3,994,923	11/1976	Miles, Peter et al.			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Sub Class	Translation	Abstract
	95/01096	1/1995	WO				
	97/03055	1/1997	WO				
	199650598 B2	2/1999	AU				
	00/31060	6/2000	WO				
	98/27970	7/1998	WO				
	0 236 929A	9/1987	EP				
	0 641 792A	3/1995	EP				
	94/16563A	8/1994	WO				
	62187410	8/1987	JP				
	7112978	5/1995	JP				
	4343592	6/1995	DE				

Relief 12/14/04

Form PTO-1449			Complete if Known		
US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			Application Number	10/612,476	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)			Filing Date		
			First Named Inventor	Patrick T. PRENDERGAST	
			Art Unit	1614	
			Examiner Name	P. Henley	
			Confirmation No.		
Sheet	2	of	3	Attorney Docket No.	802_004 CON

**OTHER DOCUMENTS**  
(Including Author, Title, Date, Pertinent Pages etc.)

	Benson, A., "Oltipraz: a laboratory and clinical review," <u>J. Cell Biochem.</u> , Supp. 17F, pp. 278-91 (1993)
	Langouet, S., et al., "Inhibition of Human Cytochrome P450 Enzymes by 1,2-Dithiole-3-thione, Oltipraz and Its Derivatives, and Sulforaphane," <u>Chem. Res. Toxicol.</u> , Vol. 13(4), pp. 245-252 (2000)
	Fleury, M., "Action mechanism of an antischistosomal drug developed by Rhone-Poulenc Sante: 35972 RP, Oltipraz," <u>Actual. Chim.</u> , Vol. 3, pp. 123-8 (1990)
	Curphey, T., et al., "A new synthesis of 3H-1,2-dithiole-3-thiones," <u>Tetrahedron Lett.</u> , Vol. 34, pp. 3703-6 (1993)
	Maxuitenko, Y., et al., "Evaluation fo the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis," <u>Carcinogenesis</u> , Vol. 14, pp. 2423-5 (1993)
	Martens, T., et al. "Electrochemical reduction of substituted isothiazole-3-thiones in aprotic media," <u>J. Chem. Soc., Perkin Trans. 2</u> , pp. 1763-8 (1991)
	Vaccher, C., et al., "Electro-organic synthesis and x-ray crystal structure of the novel complex 2,7-dimethyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazinium triiodomercurate(II)," <u>J. Chem. Soc., Perkin Trans. 2</u> , pp. 391-4 (1989)
	Largerion, M., et al., "Studies of the reaction of substituted 1,2-dithiole-3-thiones and -3-ones with sodium cynatide in acetonitrile," <u>J. Heterocycl. Chem.</u> , Vol. 25, pp. 1223-5 (NO DATE PROVIDED)
	Largerion, M., et al., "Reactivity of substituted 1,2-dithiole-3-thiones with sodium ethanethiolate: a conventient route toa novel heterocycle," <u>Tetrahedron</u> , Vol. 43, pp. 3421-8 (1987)
	Fleury, M., et al., "Studies of the reaction of 1,2-dithiole-3-thiones with nucleophiles," <u>Tetrahedron</u> , Vol. 41, pp. 3705-15 (1985)
	Largerion, M., et al., "Study of the reductive metabolism pathway of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione. An electrochemical approach." <u>Tetrahedron</u> , Vol. 42, pp. 409-15 (1986)
	Van Dyke, K., "The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly," <u>Med Hypotheses</u> 1997 May; 48(5): 375-80.
	Smith, Mark A., et al., "Iron accumulation in Alzheimer disease is a source of redox-generated free radicals," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp. 9866-9868 (1997)
	Ansher, S., et al., "Biochemical Effects of Dithiolthiones", <u>Fd. Chem. Toxic.</u> , Vol. 24, No. 5, pp. 405-415 (1986)
	Prochaska, H., et al., "Elevation of Glutathione Levels by Phase II Enzyme Inducers: Lack of Inhibition of Human Immunodeficiency Virus Type 1 Replication in Chronically Infected Monocytoid Cells." <u>Molecular Pharmacology</u> , Vol. 45, pp. 916-921 (1993)
	Smith, M., et al., "Widespread Peroxynitrite-Mediated Damage in Alzheimer's Disease," <u>The Journal of Neuroscience</u> , Vol. 17(8), pp. 2653-2657 (1997)
	Behl, C., et al., "Hydrogen Peroxide Mediates Amyloid $\beta$ Protein Toxicity," <u>Cell</u> , pp. 817-827, (1994)

*R. P. Henley 12/14/04*

Form PTO-1449				Complete if Known	
US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				Application Number	10/612,476
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Filing Date	
				First Named Inventor	Patrick T. PRENDERGAST
				Art Unit	1614
				Examiner Name	R. Herley
				Confirmation No.	
Sheet	3	of	3	Attorney Docket No.	802_004 CON
				Butterfield, D., et al., "β-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer's Disease," <u>Biochemical and Biophysical Research Communications</u> , Vol. 200, No. 2, pp. 710-715 (1994)	
				Good, P., et al., "Selective Accumulation of Aluminum and Iron in the Neurofibrillary Tangles of Alzheimer's Disease: A Laser Microprobe (LAMMA) Study," <u>Annals of Neurology</u> , Vol. 31, No. 3, pp. 286-292 (1992)	
				Drukarch, B., et al., "Drug treatment of Parkinson's disease. Time for Phase II." <u>Biochemical Pharmacology</u> , 59/9, 1023-1031 (2000)	
				Tirosh, Oren, et al., "Neuroprotective effects of alpha-lipoic acid and its positively charged amide analog", <u>Free Radical Biol. Med.</u> 22 (11/12), 1418-1426 (1999)	
				Dringen, Ralf et al., "Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells", <u>Naunyn-Schmiedeberg's Arch. Pharmacol.</u> 358(6), 616-622 (1998)	
				Drukarch, Benjamin, et al., "Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes", <u>Eur. J. Pharmacol.</u> 329 (2/3), 259-262 (1997)	
				Rangan et al., <u>British Medical Bulletin</u> , Vol. 49, No. 3, pp. 700-718, 1993	
				Stoof, et al., <u>European Journal of Pharmacology</u> , Vo.. 375, No. 1-3, pp. 75-86, June 1999	

Examiner:	<i>R. Herley</i>	Date Considered:	12/14/04
-----------	------------------	------------------	----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.